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autosomal-dominant polycystic kidney disease.
Background. The relationship between the progress of tubu-
lar damage and renal insufficiency in autosomal-dominant
polycystic kidney disease (ADPKD) is a subject of doubtless
interest, and is the object of this present work.
Methods. A total of 92 adult ADPKD patients of both gen-
ders were studied, none of which presented end-stage renal dis-
ease (ESRD), and classified according to an ultrasound score
based on kidney size and number of cysts. Urinary albumin and
b-N-acetylhexosaminidase (Hex) and its isoenzymes were de-
termined, together with serum glutathione peroxidase, cystatin
C, creatinine, and urea.
Results. A frequent elevation of the urinary Hex was found
and an alteration of its isoenzymatic profile, with 31% of the
normotensive patients with normoalbuminuria already present-
ing an increased proportion of Hex B isoenzyme. Keeping age
constant, a partial significant correlation was found between
the ultrasound score and the proportion of Hex B (r = 0.352,
P < 0.05), but not with albuminuria or cystatin C. In 42 patients
the different biochemical variables were again determined af-
ter 1 year, finding that in the 13 normotensive patients with
normoalbuminuria there had been a significant decrease in the
concentration of cystatin C (P < 0.05), and a significant increase
in the urinary excretion of albumin and Hex B isoenzyme (P <
0.05). By the other hand, in the other 29 patients with micro- or
macroalbuminuria and hypertension, no significant differences
were found.
Conclusion. The results point toward an important partici-
pation of tubular damage in the pathogenesis of this disease.
It may also be suggested that in normotensive and normoalbu-
minuric ADPKD patients, a gradual increase of glomerular fil-
tration would be produced. After the start of hypertension and
microalbuminuria, the glomerular filtration rate (GFR) would
decrease progressively, although more slowly.
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Autosomal-dominant polycystic kidney disease
(ADPKD) is the most common monogenetic hereditary
disease, which affects 1 in 400 to 1000 live births [1].
Renal manifestation is the most prominent feature which
accounts for 5% of the end-stage renal disease (ESRD)
population in worldwide; however, ADPKD is a system
disorder involving a variety of other organs [2, 3]. The
rate of progression of renal insufficiency is variable
[3], and the ESRD occurs in only approximately 50%
of affected subjects [4]. Negative prognostic factors to
renal failure are male gender, presence of early onset of
hypertension, increased renal size, and increased urinary
excretion of albumin [3].
Based on the first electrophoretic studies carried out
in urine samples from patients with polycystic kidney dis-
ease (PKD), it was indicated that in the initial stage of the
illness with a conserved glomerular filtration rate (GFR),
the proteinuria would be quantitatively and qualitatively
normal, or of a highly selective glomerular type [5]. Once
deterioration of renal function has started, the protein-
uria would be of a barely selective glomerular type, and
only in more advanced stages of renal insufficiency it
would be of a mixed, glomerular and tubular type [5].
The increase of urine albumin without an increase in low
molecular protein is considered to be an early marker of
glomerular damage [6], and in the ADPKD patients mi-
croalbuminuria is more common than proteinuria [3]. Mi-
croalbuminuria in these patients may be associated with
an increase in arterial pressure [7–9], progression to re-
nal insufficiency [8], as well as with a more severe cystic
involvement [7]. However, in normotensive ADPKD pa-
tients, microalbuminuria would have an increased preva-
lence [10].
Increased urinary excretion of b-N-acetylhexo-
saminidase (Hex) (EC 3.2.1.52) indicates a direct re-
lease of proximal tubular material into the urine [6, 11].
Swedenborg, Hultberg, and Thysell [12] found an in-
crease in the urinary activity of Hex in patients with
PKD, which would be related to changes in serum cre-
atinine produced over the period of 1 year. This is inter-
esting data, as taking into consideration the structural
948
Casal et al: Three biomarker tests in ADPKD 949
and functional renal alterations found in rats with
dyphenylthiazole-induced PKD, it has been suggested
that renal functional impairment in the clinical forms of
PKD may be due primarily to tubular rather glomerular
or vascular alterations [13].
In this article a comparative study is made of 92 pa-
tients with ADPKD for three biomarker tests of early
kidney damage such as urinary albumin and total Hex
activity and its isoenzymes, as well as serum glutathione
peroxidase (GPx) (Ec 1.11.1.9), which has been consid-
ered as a marker of renal proximal tubular function [14].
Similarly, GPx is an important antioxidant enzyme, and a
number of observations suggest that the severity of PKD
may be modulated by oxidative stress [15]. At the same
time, a determination was made of the kidney dysfunction
markers serum cystatin C, creatinine, and urea.
METHODS
A total of 92 ADPKD patients (42 males and 50 fe-
males) with a mean age (± SEM) of 42.3 ± 1.5 years
(range 14 to 83 years) were studied, whose diagnosis was
made on the basis of family history, typical ultrasound
findings, and genetic testing. Thirty-five patients were
normotensive and 57 presented with arterial hyperten-
sion and were taking antihypertensive drugs, preferen-
tially angiotensin-converting enzyme (ACE) inhibitors
and angiotensin II receptor antagonists. According to
the rate of urinary albumin excretion and serum concen-
tration of cystatin C, the patients were classified in the
following groups: (1) normoalbuminuria, (2) microal-
buminuria, (3) macroalbuminuria, and (4) renal insuf-
ficiency (serum cystatin C >1.3 mg/L). Also, using the
ultrasound findings, the patients were classified into three
further groups: (1) those with fewer than 10 cysts in each
kidney (ultrasound score 1), (2) those with slightly en-
larged kidneys and more than 10 cysts in each (ultrasound
score 2), and (3) those with significantly enlarged kidneys
and a large number of cysts (ultrasound score 3). In 42
of these patients who returned for follow-up (7 with and
35 without renal insufficiency), the urinary excretion of
albumin and Hex and the serum concentrations of cys-
tatin C, creatinine, and urea were determined, carrying
out a second analysis of these biochemical variables after
1 year. The relative changes during this period of time
were calculated using the expression:
relative change (%) = 100(V2 − V1)/V1
where V1 is the first value and V2 is the second value. As
a control group, a total of 54 clinically healthy individuals
were studied with a similar distribution by age and gen-
der. Blood samples were taken in the morning without
any food intake, also collecting the second urine miction
of the day in line with the recommendations of Itoh et al
[16], to prevent obtaining false Hex activities as a result
of contamination with enzymes of genital origin. In all of
the cases the urine samples presented a value of pH <8.
The total urinary Hex activity and the thermo-
dynamic evaluation of its isoenzyme composi-
tion were determined using the neutral substrate
3,3′-dichlorophenalsulfonphthaleinyl-N-acetyl-b-D-
glucosaminide as previously described [17]. The
apparent enzyme activation energy is directly related
to the relative proportions of the isoenzymes Hex A
(ab heterodimer) and Hex B (bb homodimer), because
the presence of the a subunit in Hex A gives it an
activation energy that is significantly lower than that of
Hex B isoenzyme [18]. The results were expressed as
the ratio of urinary Hex activity to urinary creatinine
concentration and reported in U/g. The albumin in urine
was quantified by means of a nephelometric assay using
commercial reagents from Dade Behring (Liederbach,
Germany). The results were expressed as the ratio of
urinary albumin to urinary creatinine concentrations
(ACR) and reported in mg/g. In accordance with the
American Diabetes Association recommendations [19],
normoalbuminuria was defined as an ACR of less than
30 mg/g, microalbuminuria as an ACR of 30 to 300 mg/g
and macroalbuminuria as an ACR greater than 300
mg/g. Serum GPx (mass) was determined by means a
polyclonal antibody specific for the human plasma extra-
cellular enzyme form (GPx3), using the enzyme-linked
immunoassay (Bioxytech pl.GPx-EIA) commercialized
by Oxis International Inc. (Portland, OR, USA). Serum
cystatin C was determined using a particle-enhanced im-
munoturbidimetric assay (Dako Cytomation, Glostrup,
Denmark). Creatinine and urea determinations were
performed using standard procedures in an Advia 1650
analyzer (Bayer Corp., Tarrytown, NY, USA).
Statistical analysis of the data was carried using the
Microsoft Excel (version 5.0) package. The Kolmogorov-
Smirnov test was applied to check for normality.
Parametric tests (Student t test and Pearson correlation
coefficient) were used when the data had Gaussian distri-
bution; otherwise, nonparametric tests (Mann-Whitney
test and Spearman correlation coefficient) were used. The
results were expressed as mean ± SEM (median).
RESULTS
The results obtained for the different variables studied
in the control group and the groups of ADPKD patients
are shown in Table 1. A dichotomy of the patients ac-
cording to gender did not appear to offer any information
with additional interest. In the case of serum GPx, no sta-
tistically significant differences were found between the
different groups. The calculated reference ranges for the
urinary excretion of Hex in the control group were 1.0
to 4.4 U/g creatinine for total Hex (log normal distribu-
tion), 0.9 to 3.4 U/g creatinine for Hex A (log normal
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Table 1. Levels of the biochemical variables studied in the controls and the groups of autosomal-dominant polycystic kidney disease (ADPKD)
patients
Patients
Normoalbuminuria Microalbuminuria Macroalbuminuria Renal insuficiency
Controls (N = 54) (N = 42) (N = 20) (N = 2) (N = 28)
Total Hex U/g 2.27 ± 0.11 (2.05) 1.98 ± 0.17 (1.87) 3.69 ± 0.70 (2.85) 2.73 ± 1.22 (2.73) 8.00 ± 0.84 (6.41)
Hex A U/g 1.85 ± 0.09 (1.70) 1.49 ± 0.12 (1.36) 2.56 ± 0.52 (2.04) 1.83 ± 0.70 (1.83) 5.22 ± 0.61 (4.89)
Hex B U/g 0.42 ± 0.04 (0.42) 0.68 ± 0.09 (0.55) 1.40 ± 0.26 (1.20) 0.89 ± 0.51 (0.89) 2.78 ± 0.28 (2.42)
Hex B% 16.90 ± 1.37 (18.41) 29.90 ± 2.87 (32.81) 34.74 ± 2.78 (34.42) 30.43 ± 5.28 (30.43) 37.03 ± 2.10 (37.12)
GPx ng/mL 47.15 ± 2.97 (43.00) 47.43 ± 2.82 (43.80) 41.88 ± 5.63 (37.60) 37.8 ± 4.62 (37.8) 41.41 ± 4.56 (38.82)
Albuminuria mg/g — 13.95 ± 1.37 (10.63) 79.87 ± 12.63 (62.12) 456.72 ± 129.11 (456.72) 474.50 ± 129.14 (177.47)
Cystatin C mg/L — 1.07 ± 0.03 (1.07) 1.11 ± 0.04 (1.14) 0.97 ± 0.02 (0.97) 2.52 ± 0.18 (2.19)
Creatinine mg/dL — 0.89 ± 0.03 (0.86) 0.97 ± 0.05 (0.99) 0.79 ± 0.10 (0.79) 2.85 ± 0.41 (1.82)
Urea mg/dL — 38.83 ± 1.61 (39.00) 46.9 ± 2.51 (45.50) 27.00 ± 4.00 (27.00) 103.64 ± 12.52 (84.00)
Age years 32.04 ± 1.67 (30.05) 37.24 ± 1.61 (38.50) 37.20 ± 1.48 (36.5) 19.50 ± 1.50 (19.50) 55.07 ± 2.66 (54.00)
Abbreviations are: Hex, b-N-acetylhexosaminidase; GPx, glutathione peroxidase.
Table 2. Levels of the biochemical variables studied in the normo- and hypertensive autosomal-dominant polycystic kidney disease (ADPKD)
patients
Normoalbuminuria Microalbuminuria
Normotensive (N = 26) Hypertensive (N = 16) Normotensive (N = 8) Hipertensive (N = 12)
Total Hex U/g 1.82 ± 0.14 (1.87) 2.25 ± 0.40 (1.90) 2.98 ± 0.30 (3.14) 4.16 ± 1.15 (2.70)
Hex A U/g 1.40 ± 0.13 (1.35) 1.68 ± 0.27 (1.59) 2.05 ± 0.19 (2.05) 2.89 ± 0.84 (2.02)
Hex B U/g 0.49 ± 0.07 (0.49) 1.07 ± 0.20 (0.98) 1.11 ± 0.14 (1.24) 1.58 ± 0.41 (1.16)
Hex B% 24.87 ± 3.33 (27.54) 39.95 ± 4.29 (41.50) 35.03 ± 2.64 (36.53) 34.55 ± 4.35 (30.03)
GPx ng/mL 42.90 ± 2.16 (42.60) 55.51 ± 6.43 (50.88) 34.96 ± 3.52 (36.25) 45.35 ± 8.21 (39.80)
Albuminuria mg/g 11.70 ± 1.65 (9.52) 17.63 ± 2.16 (19.14) 89.40 ± 27.41 (70.76) 73.52 ± 11.44 (62.12)
Cystatin C mg/L 1.03 ± 0.04 (1.00) 1.12 ± 0.04 (1.05) 1.07 ± 0.05 (1.06) 1.14 ± 0.05 (1.15)
Creatinine mg/dL 0.85 ± 0.03 (0.80) 0.95 ± 0.04 (0.92) 0.90 ± 0.08 (0.91) 1.01 ± 0.06 (1.02)
Urea mg/dL 36.65 ± 1.75 (37.00) 42.37 ± 3.01 (44.50) 44.87 ± 3.97 (44.50) 48.25 ± 3.33 (48.00)
Age years 33.88 ± 2.01 (37.00) 42.69 ± 2.08 (41.50) 37.0 ± 2.85 (34.50) 37.33 ± 1.70 (37.0)
Abbreviations are: Hex, b-N-acetylhexosaminidase; GPx, glutathione peroxidase.
distribution), 0.0 to 1.3 U/g creatinine for Hex B (non-
gaussian distribution), and 0% to 33% for the relative
proportion of Hex B (non-Gaussian distribution). The
group of patients with normoalbuminuria presented sig-
nificantly higher levels for the excretion of Hex B (P <
0.05) and the relative proportion in percentage of this
isoenzyme (P < 0.01) than the control group. In five cases
(12%) the urinary excretion of Hex B and in 18 cases
(43%) the relative proportion of Hex B was higher than
the corresponding upper reference limit. In the group
of patients with microalbuminuria, the excretion of total
Hex (P < 0.05), Hex B (P < 0.001) and the relative pro-
portion of Hex B (P < 0.001) were significantly higher
than in the control group. In three cases (15%) the ex-
cretion of total Hex, in two cases (10%) the excretion
of Hex A, in seven cases (35%) the excretion of Hex B,
and in nine cases (45%) the relative proportion of Hex
B were higher than the corresponding upper reference
limit. The group of patients with microalbuminuria pre-
sented significantly higher levels than the group of pa-
tients with normoalbuminuria for total Hex (P < 0.005),
Hex A (<0.01), and Hex B (P < 0.01), although statistical
significance was not attained for the relative proportion
of Hex B. Due to the small number of patients without
renal insufficiency presenting macroalbuminuria (N = 2)
the results of this group could not be subjected to statis-
tical treatment.
In the group of patients with renal insufficiency,
five cases (18%) presented normoalbuminuria, 13 cases
(46%) microalbuminuria, and 10 cases (36%) macroalbu-
minuria. In these patients the excretion of total Hex, Hex
A, Hex B, and the relative proportion of Hex B were all
significantly higher than in the control group (P < 0.001)
presenting, respectively, in 79%, 57%, 86%, and 61% of
the cases higher values than the corresponding upper ref-
erence limits. Between the groups with renal insufficiency
and the group with microalbuminuria, significant differ-
ences were found for the excretion of total Hex (P <
0.001), Hex A (P < 0.001), and Hex B (P < 0.001), al-
though not for the proportion of Hex B.
On carrying out a dichotomy of the patients without
renal dysfunction depending on whether they were hy-
pertensive or not, the results indicated in Table 2 were
found. In the group of patients with normoalbuminuria,
the hypertensive subjects presented an excretion of Hex
B (P < 0.05) and proportion of Hex B (P < 0.01) that
were significantly higher than the normotensive subjects.
In the subgroup of normotensive patients, for eight cases
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Table 3. Correlation between the biochemical variables studied in
the autosomal-dominant polycystic kidney disease (ADPKD) patients
(N = 92)
Total Hex Hex A Hex B
Hex A 0.944a
Hex B 0.893a 0.724a
GPx −0.255b −0.173 0.145
Albuminuria 0.630a 0.602a 0.627a
Cystatin C 0.558a 0.499a 0.613a
Creatinine 0.501a 0.453a 0.540a
Urea 0.470a 0.386a 0.520a
Abbreviations are: Hex, b-N-acetylhexosaminidase; GPx, glutathione
peroxidase.
aP < 0.001; bP < 0.05.
(31%) the relative proportion of Hex B was higher than
the upper reference limit. In the subgroup of hyperten-
sive patients, the excretion of Hex B was increased in five
cases (31%) and the relative proportion of Hex B in 10
cases (62%). In the group of patients with microalbumin-
uria, no significant differences were found for the excre-
tion of Hex and its isoenzymes between the subgroups of
normo- and hypertensive patients. No patient with renal
insufficiency was normotensive.
Table 3 shows the correlation coefficients between Hex
and its isoenzymes with the different biochemical vari-
ables studied in the total number of ADPKD patients.
Cystatin C presented a highly significant correlation with
creatinine (r = 0.736, P < 0.001) and urea (r = 0.661,
P < 0.001). The ultrasound score presented significant
correlations with total Hex (r = 0.350, P < 0.01), Hex
A (r = 0.332, P < 0.01), Hex B (r = 0.445, P < 0.01),
Hex B percentage (r = 0.333, P < 0.01), albuminuria (r =
0.433, P < 0.01), and cystatin C (r = 0.346, P < 0.01), as
well as with the patients’ age (r = 0.507, P < 0.01). As all
of these biochemical variables, except the proportion of
Hex B isoenzyme, presented significant correlations with
age (P < 0.01), a study was made of the partial correla-
tions, only reaching significance between the ultrasound
score and the proportion of Hex B (r = 0.352, P < 0.01).
In 42 patients, at the end of 1 year a second determi-
nation was made of the urinary excretion of Hex and
albumin as well as the serum concentrations of cystatin
C, creatinine, and urea. In 13 of these patients (five males
and eight females) with a mean age of 37.0 ± 2.5 years
(range 22 to 49 years), who were normotensive and who
presented normoalbuminuria, the concentration of cys-
tatin C at the end of this period of one year was 0.86 ±
0.04 mg/L (0.81 mg/L), significantly lower (P < 0.05) than
the initial value of 1.09 ± 0.06 mg/L (1.05 mg/L), as shown
in Figure 1. In accordance with the results of Larsson et al
[20], these concentrations of serum cystatin C correspond
to GFR values of 131.5 ± 9.4 mL/min (142.0 mL/min) and
85.0 ± 8.9 mL/min (92.0 mL/min), respectively (P < 0.01).
During this period of time the urinary excretion of Hex B
isoenzyme and albumin increased significantly (P < 0.05),
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Fig. 1. Evolution of serum cystatin C concentration during the period
of one year in 13 normotensive autosomal-dominant polycystic kidney
disease (ADPKD) patients with normoalbuminuria. Baseline mean =
1.09 ± 0.06 mg/L; 1-year mean = 0.86 ± 0.04 mg/L (P < 0.05).
with no significant differences detected for creatinine and
urea. In the other 29 patients (10 males and 19 females)
with a mean age of 40.5 ± 2.1 years (range 25 to 74 years),
and with hypertension and micro- or macroalbuminuria,
no significant differences were found between the first
and second values for serum cystatin C, creatinine, and
urea, or for the urinary excretion of Hex and albumin.
In the total group of these 42 patients, a significant cor-
relation was found between the relative changes during
the period of 1 year for cystatin C with the initial values
of Hex B (r = 0.336, P < 0.05), and better with the pro-
portion in percentage of Hex B (r = 0.537, P < 0.01) as
it is shown in Figure 2. For the 29 hypertensive/micro-
or macroalbuminuric patients, the correlation between
these variables was significant (r = 0.378, P < 0.05); how-
ever, in the 13 normotensive/normoalbuminuric patients
a significant correlation was not achieved (r = 0.276).
The relative changes of cystatin C or creatinine did not
present a significant correlation with the initial values of
albuminuria. However, the relative changes for albumin-
uria presented significant correlations with the relative
changes of total Hex (r = 0.390, P < 0.05) and Hex A
(r = 0.456, P < 0.01), although not with those of Hex B.
DISCUSSION
Serum creatinine is an insensitive test because over
50% of the renal function is lost before changes occur in
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Fig. 2. Relationship between serum cystatin C relative change dur-
ing the period of 1 year and the first values of the urinary b-N-
acetylhexosaminidase (Hex B) proportion in 42 autosomal-dominant
polycystic kidney disease (ADPKD) patients. Normotensive patients
with normoalbuminuria (◦); hypertensive and micro- or macroalbu-
minuric patients (•).
its values [21]; however, serum cystatin C reportedly starts
to increase as the GFR falls below about 80 mL/min, and
therefore is particularly useful when trying to detect mild
impairment of renal function [21, 22]. Taking into account
the reference values established in our laboratory, a cut-
off level of serum cystatin C >1.3 mg/L was considered
as a marker for renal insufficiency. These concentrations
corresponded to values of GFR <66 mL/min [20], which
are in accordance with the proposed definition of chronic
kidney disease based on the level of kidney function [23].
Using this criterion, 28 of the 92 ADPKD patients studied
presented renal insufficiency, without reaching ESRD in
any case. The other 64 patients presented a variable level
of kidney damage with normal or only mildly diminished
GFR.
As shown in Table 1, no significant differences were
found for the serum levels of GPx mass among the dif-
ferent groups of patients and with regard to the con-
trol group. The dichotomy of the patients depending on
whether they were normotensive or hypertensive not
provided additional data of interest. These results ap-
pear to be quite surprising, as extracellular selenium–
dependent GPx is primarily synthesized in the kidney
proximal tubule epithelium [24], and its serum/plasma en-
zyme activity appears significantly reduced in most renal
diseases [14, 25–27]. Some authors have attributed these
low activities to a decrease in GPx production in the dam-
aged kidney tissue [25]. However, few studies have exam-
ined the levels of GPx mass, and Roxborough et al [27]
suggest that the reduction of serum activity in chronic re-
nal failure is not due to a decrease on the enzyme protein
synthesis but to enzyme inactivation. According to these
authors, renal failure per se rather than the underlying
disease is the main cause of decreased GPx activity due
to oxidative damage, glycation or carbamilation of the
enzyme protein [27]. The reduction of plasma GPx ac-
tivity has also been attributed to selenium deficiency [28,
29]. Further studies are necessary to establish the cause
of lowered plasma GPx activity in renal disease [29].
As mentioned above, in the ADPKD patients we stud-
ied, none of whom presented end-stage renal failure, no
significant variations were found for the serum levels of
GPx in relation to the control group. In turn, neither did
Shiavon et al [25] find any significant decreases of plasma
GPx activity in patients with tubulointerstitial disease due
to aminoglucosides. In any case, the negative correlation
found in our ADPKD patients between the urinary ex-
cretion of total Hex and the serum levels of GPx (P <
0.05), suggest that these may be partially conditioned by
renal proximal tubular involvement.
The results shown in Tables 1 and 2 demonstrate that
in ADPKD the urinary excretion of total Hex, as well
as its isoenzymatic profile, is prematurely altered. In the
group of patients with normoalbuminuria and normal re-
nal function, a significant increase in the excretion of
Hex B was detected (P < 0.05), as well as the relative
proportion of this isoenzyme (P < 0.001), with signifi-
cance increasing on considering the subgroup of hyper-
tensive patients. Previous studies have shown that in arte-
rial hypertension, the urinary excretion of Hex is altered
earlier than other renal markers, suggesting that tubu-
lar injury may precede glomerular damage in the earlier
stages of hypertensive nephropathy [30, 31]. However, it
is interesting to note that in the subgroup of normoten-
sive patients with normoalbuminuria, 31% of the cases
already presented an altered isoenzymatic profile with
an increase in the proportion of Hex B. As described
later in this article, this variable may present a significant
association with changes in renal function.
In the group of patients with microalbuminuria, the
excretion of total Hex and Hex B was significantly in-
creased (P < 0.001), with no differences found between
the subgroups of normo- and hypertensive patients. An
increased urinary albumin excretion usually reflects a
glomerular disease, but when the quantity is small it may
be due to impaired tubular resorption, and consequently
microalbuminuria is commonly found in patients with re-
nal tubular disorders [32].
The increase of urinary Hex is considered a marker
of the intensity of proximal tubular involvement in re-
nal disease [9, 10], even in patients with proteinuria due
to a damaged glomerular basement membrane [33, 34].
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However, the urinary excretion of Hex must be inter-
preted with caution, as it may be a marker of the tubular
functional status as well as tubular damage [11]. An in-
creased lysosomal turnover, as a result of stimulation of
endocytic lysosomal system, may occur when increased
protein is presented to the tubular cells [11]. In conse-
quence, in patients with an increased albumin excretion,
the urinary Hex activity may reflect lysosomal activation
as well as tubular damage.
The clinical value of urinary Hex may be enhanced
by determining its isoenzymes. Under normal physio-
logic conditions, the urinary excretion of Hex is almost
wholly originated from renal enzyme secreted by exocy-
tosis of the lysosomal content. This functional enzymuria
is linked to the major excretion of Hex A isoenzyme local-
ized in the soluble intralysosomal compartment [35–37].
However, in cases of tubular damage with cell necrosis,
lesional enzymuria is characterized by an increased excre-
tion of the Hex B isoenzyme, which is essentially localized
in the lysosomal membrane [35–37]. A recent study sug-
gests that the association of Hex with the membranes is
not likely to be through the glycosylphosphatidyl inositol
anchor, but this enzyme would be an integral membrane
protein [38].
Different studies have shown the existence of signif-
icant correlations between urinary Hex and proteinuria
[33, 39–41] and albuminuria [40] in different renal dis-
eases. Functional changes in the renal tubular cells caused
by protein resorption may be responsible for this associa-
tion [40]. In our ADPKD patients, highly significant cor-
relations were found for albuminuria with the excretion
of total Hex, Hex A, and Hex B (P < 0.001). In the 42 pa-
tients whose urinary Hex and albumin were determined
after 1 year, a significant correlation was found between
the relative changes in albuminuria during this period and
those of Hex A (P < 0.01), although not with those of Hex
B. These results may be explained taking into account the
fact that a possible tubular lysosomal activation would
favor the excretion of Hex A isoenzyme; however, the
urinary albumin (structurally modified) could also pro-
duce tubular injury [42] and would mask the association
between the relative changes for albuminuria and urinary
Hex A. Also in these patients, a significant correlation was
found between the relative changes in cystatin C during
1 year with the initial values for Hex B (P < 0.05) and the
proportion of Hex B (P < 0.01), although not with those
of Hex A. An increased urinary excretion of Hex B, and
consequently of its relative proportion, may be related to
tubular injury, whose central role in the progressive loss
of renal function in most chronic forms of renal diseases
has been recently highlighted [43].
Discordant results were obtained by different au-
thors for the relationship between renal enlargement,
cyst expansion, and renal dysfunction [44–46], although
structure-function relationships are present when more
accurate and reliable imaging methods are used. It has
been suggested that both genetic and environmental fac-
tors may influence the severity and progression of renal
disease in human ADPKD by modulating the renal cyst
number and size and consequently renal volume [2]. Re-
nal enlargement, hypertension, gender, proteinuria, and
decline in GFR are related; however, other unidentified
factors also are likely determinants of renal function de-
cline in patients with ADPKD [45]. In our patients, no
significant partial correlation was detected, keeping the
patients’ age constant, between the ultrasound score used
and serum concentration of cystatin C. These results are
concordant with those of Wong et al [44], who were also
unable to discover any significant relationship between
renal length or the number of cysts with GFR in their
ADPKD patients. The fact that a significant partial cor-
relation was detected in our study between the ultrasound
score and the relative proportion of urinary Hex B indi-
cates the tubular damage implication in the pathogenesis
of this disease.
After the period of 1 year, no significant modification
was found for any of the biochemical variables studied
in the group of 29 patients with hypertension and micro-
or macroalbuminuria. However, it does appear notewor-
thy that in the group of 13 normotensive patients with
normoalbuminuria, the serum concentration of cystatin
C decreased significantly (see Fig. 1), with a significant
increase, on the contrary, of the urinary excretion of Hex
B isoenzyme and albumin (P < 0.05). In line with previ-
ous results of Chapman et al [abstract; Chapman A, et al,
Kidney Int 35:203A, 1989] and Wong et al [44], glomeru-
lar hyperfiltration appears to be an early manifestation
of ADPKD, which may be revealed through the serum
concentration of cystatin C, and that may precede the
onset of microalbuminuria and hypertension [44]. As was
expected, hyperfiltration was more prevalent in children
and adolescents than in adult ADPKD patients [abstract;
Chapman A, et al, Kidney Int 35:203A, 1989]. However,
considering our results, it may be suggested as a hypothe-
sis that even in adult ADPKD patients who do not present
hypertension and microalbuminuria, a gradual increase
would be produced in glomerular filtration. Once mi-
croalbuminuria and hypertension appear, there is a pro-
gressive yet slower decrease of GFR in these patients.
A minor form of Hex located in the cytoplasm, and
which has been named Hex C, appears increased in neo-
plastic renal tissues [47]. As the concept that polycystic
kidney is a neoplasm in disguise is gaining in acceptance
[15], the possible presence of the Hex C isoenzyme in the
urine of ADPKD patients is the subject of a further study.
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